1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar
|
2
|
Thomas A and Hassan R: Immunotherapies for
non-small-cell lung cancer and mesothelioma. Lancet Oncol.
13:e301–e310. 2012. View Article : Google Scholar : PubMed/NCBI
|
3
|
Reck M: What future opportunities may
immuno-oncology provide for improving the treatment of patients
with lung cancer? Ann Oncol. 23(Suppl 8): viii28–viii34. 2012.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Loskog AS and Eliopoulos AG: The Janus
faces of CD40 in cancer. Semin Immunol. 21:301–307. 2009.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Khong A, Nelson DJ, Nowak AK, et al: The
use of agonistic anti-CD40 therapy in treatments for cancer. Int
Rev Immunol. 31:246–266. 2012. View Article : Google Scholar : PubMed/NCBI
|
6
|
Ullenhag G and Loskog AS: AdCD40L -
crossing the valley of death? Int Rev Immunol. 31:289–298. 2012.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Vonderheide RH and Glennie MJ: Agonistic
CD40 antibodies and cancer therapy. Clin Cancer Res. 19:1035–1043.
2013. View Article : Google Scholar : PubMed/NCBI
|
8
|
Pietravalle F, Lecoanet-Henchoz S, Blasey
H, et al: Human native soluble CD40L is a biologically active
trimer, processed inside microsomes. J Biol Chem. 271:5965–5967.
1996. View Article : Google Scholar : PubMed/NCBI
|
9
|
Georgopoulos NT, Steele LP, Thomson MJ, et
al: A novel mechanism of CD40-induced apoptosis of carcinoma cells
involving TRAF3 and JNK/AP-1 activation. Cell Death Differ.
13:1789–1801. 2006. View Article : Google Scholar : PubMed/NCBI
|
10
|
Goules A, Tzioufas AG, Manousakis MN, et
al: Elevated levels of soluble CD40 ligand (sCD40L) in serum of
patients with systemic autoimmune diseases. J Autoimmun.
26:165–171. 2006. View Article : Google Scholar : PubMed/NCBI
|
11
|
Ferroni P, Santilli F, Guadagni F, et al:
Contribution of platelet-derived CD40 ligand to inflammation,
thrombosis and neoangiogenesis. Curr Med Chem. 14:2170–2180. 2007.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Elmetwali T, Young LS and Palmer DH: CD40
ligand-induced carcinoma cell death: a balance between activation
of TNFR-associated factor (TRAF) 3-dependent death signals and
suppression of TRAF6-dependent survival signals. J Immunol.
184:1111–1120. 2010. View Article : Google Scholar
|
13
|
Wu JQ, Zhao WH, Li Y, et al:
Adeno-associated virus mediated gene transfer into lung cancer
cells promoting CD40 ligand-based immunotherapy. Virology.
368:309–316. 2007. View Article : Google Scholar : PubMed/NCBI
|
14
|
Masuta Y, Kato K, Tomihara K, et al: Gene
transfer of noncleavable cell surface mutants of human CD154
induces the immune response and diminishes systemic inflammatory
reactions. J Immunother. 30:694–704. 2007. View Article : Google Scholar : PubMed/NCBI
|
15
|
Wu J, Zhao W, Zhong L, et al:
Self-complementary recombinant adeno-associated viral vectors:
packaging capacity and the role of rep proteins in vector purity.
Hum Gene Ther. 18:171–182. 2007. View Article : Google Scholar : PubMed/NCBI
|
16
|
Gomes EM, Rodrigues MS, Phadke AP, et al:
Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154)
transgene construct in human breast cancer cells. Clin Cancer Res.
15:1317–1325. 2009. View Article : Google Scholar : PubMed/NCBI
|
17
|
Vardouli L, Lindqvist C, Vlahou K, et al:
Adenovirus delivery of human CD40 ligand gene confers direct
therapeutic effects on carcinomas. Cancer Gene Ther. 16:848–860.
2009. View Article : Google Scholar : PubMed/NCBI
|
18
|
Dzojic H, Loskog A, Tötterman TH and
Essand M: Adenovirus-mediated CD40 ligand therapy induces tumor
cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate
cancer model. Prostate. 66:831–838. 2006. View Article : Google Scholar : PubMed/NCBI
|
19
|
Iida T, Shiba H, Misawa T, et al:
Adenovirus-mediated CD40L gene therapy induced both humoral and
cellular immunity against rat model of hepatocellular carcinoma.
Cancer Sci. 99:2097–2103. 2008. View Article : Google Scholar : PubMed/NCBI
|
20
|
Serba S, Schmidt J, Wentzensen N, et al:
Transfection with CD40L induces tumour suppression by dendritic
cell activation in an orthotopic mouse model of pancreatic
adenocarcinoma. Gut. 57:344–351. 2008. View Article : Google Scholar : PubMed/NCBI
|
21
|
Lindqvist C, Sandin LC, Fransson M and
Loskog A: Local AdCD40L gene therapy is effective for disseminated
murine experimental cancer by breaking T-cell tolerance and
inducing tumor cell growth inhibition. J Immunother. 32:785–792.
2009. View Article : Google Scholar : PubMed/NCBI
|
22
|
von Euler H, Sadeghi A, Carlsson B, et al:
Efficient adenovector CD40 ligand immunotherapy of canine malignant
melanoma. J Immunother. 31:377–384. 2008.PubMed/NCBI
|
23
|
Matthies KM, Newman JL, Hodzic A and
Wingett DG: Differential regulation of soluble and membrane CD40L
proteins in T cells. Cell Immunol. 241:47–58. 2006. View Article : Google Scholar : PubMed/NCBI
|
24
|
Davies CC, Mason J, Wakelam MJ, et al:
Inhibition of phosphatidylinositol 3-kinase- and ERK MAPK-regulated
protein synthesis reveals the pro-apoptotic properties of CD40
ligation in carcinoma cells. J Biol Chem. 279:1010–1019. 2004.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Dickey DD, Excoffon KJ, Koerber JT, et al:
Enhanced sialic acid-dependent endocytosis explains the increased
efficiency of infection of airway epithelia by a novel
adeno-associated virus. J Virol. 85:9023–9030. 2011. View Article : Google Scholar : PubMed/NCBI
|
26
|
Nonnenmacher M and Weber T: Intracellular
transport of recombinant adeno-associated virus vectors. Gene Ther.
19:649–658. 2012. View Article : Google Scholar : PubMed/NCBI
|